Philip Ferrone is an Ophthalmology physician. OpenAlex indexes 116 publications with 3,509 citations (h-index 28); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
600 Northern Blvd
Suite 216
Great Neck, NY 11021
Telephone
516-466-0390Provider last certified this registry record 8 Oct 2021.
Clinical trials
- Study Comparing 0.5mg of Ranibizumab and Higher Doses in the Treatment of Clinically Significant Diabetic Macular Edema
Sponsor: Philip J. ferrone, M.D.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
22 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Apellis Pharmaceuticals, Inc.Program year202522 payments$28,370openpaymentsdata.cms.gov ↗
- Alcon Vision LLCProgram year202511 payments$17,320openpaymentsdata.cms.gov ↗
- Regeneron Healthcare Solutions, Inc.Program year202511 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
86.1%Antineovascularisation agents84.7%Faricimab-svoa100%Part B, office-administered≥90 patientsCorticosteroid0.5%Prednisolone Acetate100%Part D≥66 patients+ 4 more classes in this area
Cancer & immunology
13.6%Complement Inhibitor9.2%Pegcetacoplan100%Part B, office-administered≥43 patientsVascular Endothelial Growth Factor Inhibitor4.4%Aflibercept100%Part B, office-administered≥191 patients+ 1 more class in this area
Cardiovascular
0.1%Beta blocker0.1%Timolol Maleate100%Part D<11 patientsAldosterone antagonist (MRA)0.1%Eplerenone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Pegcetacoplan for Geographic Atrophy Over 30 Months: Data From OAKS, DERBY, and the GALE Long-Term Extension Study
Ophthalmic surgery, lasers & imaging retina
2025 - Serial Intravitreal Methotrexate Injections to Combat Recurrent Proliferative Vitreoretinopathy in a Pediatric Patient
Journal of VitreoRetinal Diseases
2024
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Emily Chew, MD
National Eye Institute
Robert Weinreb, MD
University of California San Diego
Harry Quigley, MD
Johns Hopkins University School of Medicine
Joel Schuman, MD
Wills Eye Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”